• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    2/10/23 11:51:22 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

      

    Sensus Healthcare, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    81728J109

    (CUSIP Number)

     

    Edwin L. Solot, Jr.

    10940 Wilshire Boulevard

    Suite 1600 PMG #874

    Los Angeles, CA 90024

    (310) 471-6634

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
       
    ☒ Rule 13d-1(c)
       
    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 81728J109

     

      1. NAMES OF REPORTING PERSONS
        I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
         
        Edwin L. Solot, Jr.
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
        (a) ☐
        (b) ☐
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
         
        United States

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY EACH
    REPORTING
    PERSON WITH

     

    5.

     

    SOLE VOTING POWER

     

      1,543,645
    6.

    SHARED VOTING POWER

     

      11,200 (1)
    7.

    SOLE DISPOSITIVE POWER

     

      1,543,645
    8.

    SHARED DISPOSITIVE POWER

     

    11,200 (1)

         
      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        1,554,845
      10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

         
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

        9.49% (2)
      12.

    TYPE OF REPORTING PERSON (see instructions)

     

        IN

     

      (1) Represents shares of the issuer’s common stock held of record by the reporting person’s spouse. The reporting person may be deemed to be the beneficial owner of such shares.
      (2) Based on 16,390,419 shares of the issuer’s common stock outstanding as of December 31, 2022, as reported on the issuer’s current report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 9, 2023.

     

     

     

     

    Item 1.

     

      (a)

    Name of Issuer

     

    Sensus Healthcare, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    851 Broken Sound Pkwy., NW #215

    Boca Raton, FL 33487

     

    Item 2.

     

      (a)

    Name of Person Filing

     

    Edwin L. Solot, Jr.

         
      (b)

    Address of the Principal Office or, if none, residence

     

    10940 Wilshire Boulevard

    Suite 1600 PMG #874

    Los Angeles, CA 90024

         
      (c) Citizenship
         
        United States
         
      (d) Title of Class of Securities
         
        Common Stock, par value $0.01
         
      (e)

    CUSIP Number

     

    81728J109

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 1,554,845
         
      (b) Percent of class: 9.49%
         
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: 1,543,645
         
      (ii) Shared power to vote or to direct the vote: 11,200 (1)
         
      (iii) Sole power to dispose or to direct the disposition of: 1,543,645
         
      (iv) Shared power to dispose or to direct the disposition of: 11,200 (1)

     

    (1) Represents shares of the issuer’s common stock held of record by the reporting person’s spouse. The reporting person may be deemed to be the beneficial owner of such shares.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 10, 2023 /s/ Edwin L. Solot, Jr.
      Edwin L. Solot, Jr.

     

     

    Get the next $SRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/6/24 12:27:47 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/10/23 11:51:22 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/7/22 8:30:08 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Financials

    Live finance-specific insights

    See more
    • Sensus Healthcare Reports First Quarter 2025 Financial Results

      21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast for the next three quarters and for the full year Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shi

      5/15/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15

      Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call sta

      5/1/25 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results

      Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income

      2/5/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    SEC Filings

    See more
    • Sensus Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

      6/2/25 4:20:10 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Sensus Healthcare Inc.

      SD - Sensus Healthcare, Inc. (0001494891) (Filer)

      5/30/25 4:05:32 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Sensus Healthcare Inc.

      SCHEDULE 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      5/22/25 4:13:39 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:20:55 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:16:03 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Sensus Healthcare with a new price target

      Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

      1/31/25 9:07:11 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on Sensus Healthcare with a new price target

      Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

      11/15/24 8:09:06 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

      HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

      3/3/22 6:32:52 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Reports First Quarter 2025 Financial Results

      21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast for the next three quarters and for the full year Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shi

      5/15/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

      Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

      5/1/25 4:30:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15

      Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call sta

      5/1/25 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

      Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

      5/1/25 4:30:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Announces Retirement of Director Samuel O'Rear

      BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv

      2/1/24 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions

      BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre

      1/31/22 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Chow Carlton

      3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      6/10/25 5:33:41 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:20:55 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:16:03 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care